Back to Search Start Over

Cholesteryl Ester Transfer Protein Inhibitors

Authors :
Julian Hardy McLain
Andrew Jacob Alsterda
Rohit R. Arora
Source :
Journal of Cardiovascular Pharmacology and Therapeutics. 22:99-104
Publication Year :
2016
Publisher :
SAGE Publications, 2016.

Abstract

The cholesteryl ester transfer protein (CETP) is a plasma protein that plays an important role in the transfer of lipids between plasma lipoproteins. The CETP inhibitors have been widely studied as a pharmacologic therapy to target plasma cholesterol in order to reduce the risk of atherosclerotic cardiovascular disease . Using CETP inhibitors as cholesterol modifiers was based on the genetic research that found correlations between CETP activity and cholesterol levels. Although CETP inhibitors are successful at altering targeted cholesterol markers, recent phase 3 outcome trials have shown limited benefit on cardiovascular outcomes when combined with the current standard of care. We discuss the science of CETP inhibition, compare the CETP inhibitors developed (torcetrapib, evacetrapib, dalcetrapib, and anacetrapib), the findings from the CETP inhibitor trials, and the future outlook for CETP inhibitors in cholesterol modification.

Details

ISSN :
19404034 and 10742484
Volume :
22
Database :
OpenAIRE
Journal :
Journal of Cardiovascular Pharmacology and Therapeutics
Accession number :
edsair.doi.dedup.....be8b8951853576d4a503db48fbc79bf7
Full Text :
https://doi.org/10.1177/1074248416662349